Effect of Imatinb in the adjuvant setting on patients with resectable Gastrointestinal Stromal Tumour (GIST)
Not Applicable
- Conditions
- Gastrointestinal Stromal Tumor (GIST)
- Registration Number
- JPRN-UMIN000004989
- Lead Sponsor
- Kochi Medical School
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patients who have a medical history of active double cancers without cis in the past 5 years 2.Patients who have active infectious disease by bacteria and/or fungus 3.Patients who have heart disease of NYHA class III or IV 4.Patients who are pregnant, lactating, or with the intention of becoming pregnant (including men) 5.Patients who have mental disorder and considered inappropriate for registration to this study 6.Patients who were judged to be unacceptable for enrollment by investigators.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Recurrence-Free Survival (RFS)
- Secondary Outcome Measures
Name Time Method 1.Accomplishment rate of treatment 2.Overall survival (OS) 3.To examine factors for Imatinib treatment continuation 4.Relationship between mutation and survival term (RFS, OS) 5.Occurrence rate of adverse events